Several major pharma and biotech companies, such as Fulcrum Therapeutics, Roche, and others, are persistently working towards developing new treatment therapies for FSHD. The launch of pipeline therapies is expected to transform the treatment scenario in the coming years immensely.
DelveInsight’s “Facioscapulohumeral Muscular Dystrophy (FSHD) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Facioscapulohumeral Muscular Dystrophy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Facioscapulohumeral Muscular Dystrophy market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Facioscapulohumeral Muscular Dystrophy: An Overview
Facioscapulohumeral Muscular Dystrophy (FSHD), also known as Landouzy-Dejerine muscular dystrophy, is a disorder characterized by muscle weakness and wasting (atrophy). The disorder gets its name from muscles that are affected in the face (facio), around the shoulder blades (scapulo), and in the upper arms (humeral). Hamstring and trunk muscles are affected -early on but are less well recognized. Other arm and leg muscles are frequently eventually affected in the course of the disease.
FSHD is a genetically acquired disease that leads to progressive muscle weakness and severely decreased functional capacity in affected individuals—understanding how epigenetic factors interplay has evolved substantially in recent years.
FSHD can mimic many other genetic myopathies: particularly limb-girdle muscular dystrophy, subacute necrotizing encephalomyelopathy, acid maltase deficiency, myotonic dystrophy, and polymyositis. In cases of significant symptom overlap between myopathies, genetic testing remains the standard in distinguishing between disease pathology.
Facioscapulohumeral Muscular Dystrophy Market Key Facts
-
In 2021, the total Facioscapulohumeral Muscular Dystrophy market size was USD 25.55 million, which is expected to rise during the study period (2019–2032).
-
The total market size of FSHD in the United States was USD 19.83 million in 2021.
-
In Japan, the total market size of FSHD was USD 2.39 million in 2021.
-
In the year 2021, the total Facioscapulohumeral Muscular Dystrophy prevalent cases were 78,790 in the 7MM, which is expected to grow during the study period, i.e., 2019–2032.
-
In the 7MM, the highest number of total prevalent cases of FSHD were observed in the United States, with 33,500+ cases in 2021.
-
The total prevalent cases of FSHD in EU4 and the UK comprised 32,800+ cases in 2021.
-
According to DelveInsight’s analysis, in EU4 and the UK, the highest number of total prevalent cases of FSHD was observed in Germany in 2021.
Facioscapulohumeral Muscular Dystrophy Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Facioscapulohumeral Muscular Dystrophy market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Facioscapulohumeral Muscular Dystrophy market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Facioscapulohumeral Muscular Dystrophy Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Facioscapulohumeral Muscular Dystrophy (FSHD) Epidemiology, Segmented by –
-
Total Prevalent Cases of Facioscapulohumeral Muscular Dystrophy
-
Total Diagnosed Cases of Facioscapulohumeral Muscular Dystrophy
-
Total Type-specific Cases of Facioscapulohumeral Muscular Dystrophy
-
Total Gender-specific Cases of Facioscapulohumeral Muscular Dystrophy
-
Total Age-specific Cases of Facioscapulohumeral Muscular Dystrophy
-
Total Severity-specific Cases of Facioscapulohumeral Muscular Dystrophy
-
Total Treated Cases of Facioscapulohumeral Muscular Dystrophy
Facioscapulohumeral Muscular Dystrophy Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Facioscapulohumeral Muscular Dystrophy market or expected to be launched during the study period. The analysis covers the Facioscapulohumeral Muscular Dystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Facioscapulohumeral Muscular Dystrophy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Facioscapulohumeral Muscular Dystrophy Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-market
Facioscapulohumeral Muscular Dystrophy Therapeutics Analysis
There are currently no disease-modifying treatments for Facioscapulohumeral Muscular Dystrophy (FSHD); supportive care is the mainstay of managing FSHD. This care primarily occurs in the context of physical therapy and rehabilitation exercises. Managing pain and fatigue in FSHD patients is essential, as both symptoms can affect patient psychology. Chronic pain is manageable with analgesic and antidepressant therapy to improve the quality of life in FSHD patients. To improve the treatment scenario, globally, several key companies are actively working in the Facioscapulohumeral Muscular Dystrophy therapeutics market landscape.
The Prominent Players in the Facioscapulohumeral Muscular Dystrophy Therapeutics Market Include:
-
Fulcrum Therapeutics
-
GSK
-
Roche
And Many More
Facioscapulohumeral Muscular Dystrophy Therapies Covered in the Report Include:
-
Losmapimod: Fulcrum Therapeutics
-
RG6237: Roche
And Many Others
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Facioscapulohumeral Muscular Dystrophy Competitive Intelligence Analysis
4. Facioscapulohumeral Muscular Dystrophy Market Overview at a Glance
5. Facioscapulohumeral Muscular Dystrophy Disease Background and Overview
6. Facioscapulohumeral Muscular Dystrophy Patient Journey
7. Facioscapulohumeral Muscular Dystrophy Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Facioscapulohumeral Muscular Dystrophy Treatment Algorithm, Current Treatment, and Medical Practices
9. Facioscapulohumeral Muscular Dystrophy Unmet Needs
10. Key Endpoints of Facioscapulohumeral Muscular Dystrophy Treatment
11. Facioscapulohumeral Muscular Dystrophy Marketed Products
12. Facioscapulohumeral Muscular Dystrophy Emerging Drugs and Latest Therapeutic Advances
13. Facioscapulohumeral Muscular Dystrophy Seven Major Market Analysis
14. Attribute Analysis
15. Facioscapulohumeral Muscular Dystrophy Market Outlook (In US, EU5, and Japan)
16. Facioscapulohumeral Muscular Dystrophy Access and Reimbursement Overview
17. KOL Views on the Facioscapulohumeral Muscular Dystrophy Market
18. Facioscapulohumeral Muscular Dystrophy Market Drivers
19. Facioscapulohumeral Muscular Dystrophy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-market
Other Trending Healthcare Reports By DelveInsight
Facioscapulohumeral Muscular Dystrophy Pipeline Insight
“Facioscapulohumeral Muscular Dystrophy Pipeline Insight, 2023,” report provides comprehensive insights about 12+ companies and 12+ drugs in the Facioscapulohumeral Muscular Dystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by stage, route of administration, and molecule type. It further highlights the inactive Facioscapulohumeral Muscular Dystrophy pipeline products in this space.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/